Dr Reddy's Laboratories EBITDA 2010-2025 | RDY
Dr Reddy's Laboratories annual and quarterly EBITDA history from 2010 to 2025. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Dr Reddy's Laboratories EBITDA for the quarter ending March 31, 2025 was $0.251B, a 14.86% increase year-over-year.
- Dr Reddy's Laboratories EBITDA for the twelve months ending March 31, 2025 was $1.042B, a 5.25% increase year-over-year.
- Dr Reddy's Laboratories 2025 annual EBITDA was $1.042B, a 5.25% increase from 2024.
- Dr Reddy's Laboratories 2024 annual EBITDA was $0.99B, a 16.61% increase from 2023.
- Dr Reddy's Laboratories 2023 annual EBITDA was $0.849B, a 55.78% increase from 2022.
Dr Reddy's Laboratories Annual EBITDA
(Millions of US $) |
| 2025 |
$1,042 |
| 2024 |
$990 |
| 2023 |
$849 |
| 2022 |
$545 |
| 2021 |
$624 |
| 2020 |
$600 |
| 2019 |
$478 |
| 2018 |
$363 |
| 2017 |
$382 |
| 2016 |
$602 |
| 2015 |
$552 |
| 2014 |
$553 |
| 2013 |
$457 |
| 2012 |
$467 |
| 2011 |
$351 |
| 2010 |
$316 |
| 2009 |
$-4 |
Dr Reddy's Laboratories Quarterly EBITDA
(Millions of US $) |
| 2025-03-31 |
$251 |
| 2024-12-31 |
$274 |
| 2024-09-30 |
$256 |
| 2024-06-30 |
$261 |
| 2024-03-31 |
$219 |
| 2023-12-31 |
$252 |
| 2023-09-30 |
$261 |
| 2023-06-30 |
$258 |
| 2023-03-31 |
$179 |
| 2022-12-31 |
$238 |
| 2022-09-30 |
$239 |
| 2022-06-30 |
$193 |
| 2022-03-31 |
$48 |
| 2021-12-31 |
$164 |
| 2021-09-30 |
$204 |
| 2021-06-30 |
$129 |
| 2021-03-31 |
$149 |
| 2020-12-31 |
$157 |
| 2020-09-30 |
$168 |
| 2020-06-30 |
$150 |
| 2020-03-31 |
$144 |
| 2019-12-31 |
$145 |
| 2019-09-30 |
$150 |
| 2019-06-30 |
$161 |
| 2019-03-31 |
$127 |
| 2018-12-31 |
$129 |
| 2018-09-30 |
$110 |
| 2018-06-30 |
$112 |
| 2018-03-31 |
$84 |
| 2017-12-31 |
$126 |
| 2017-09-30 |
$104 |
| 2017-06-30 |
$49 |
| 2017-03-31 |
$105 |
| 2016-12-31 |
$126 |
| 2016-09-30 |
$94 |
| 2016-06-30 |
$57 |
| 2016-03-31 |
$113 |
| 2015-12-31 |
$153 |
| 2015-09-30 |
$179 |
| 2015-06-30 |
$157 |
| 2015-03-31 |
$169 |
| 2014-12-31 |
$146 |
| 2014-09-30 |
$120 |
| 2014-06-30 |
$135 |
| 2014-03-31 |
$123 |
| 2013-12-31 |
$159 |
| 2013-09-30 |
$144 |
| 2013-06-30 |
$90 |
| 2013-03-31 |
$127 |
| 2012-12-31 |
$99 |
| 2012-09-30 |
$141 |
| 2012-06-30 |
$93 |
| 2012-03-31 |
$193 |
| 2011-12-31 |
$163 |
| 2011-09-30 |
$66 |
| 2011-06-30 |
$94 |
| 2011-03-31 |
$63 |
| 2010-12-31 |
$87 |
| 2010-09-30 |
$110 |
| 2010-06-30 |
$74 |
| 2010-03-31 |
$8 |
| 2009-12-31 |
$79 |
| 2009-09-30 |
$74 |
| 2009-06-30 |
$93 |
| 2009-03-31 |
$204 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$13.189B |
$3.811B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
